STUDY SNAPSHOT
Who or what was studied?
Adults with obesity or overweight and a weight-related complication; diabetes was excluded.
What was measured?
Weight change and the proportion reaching a specified weight-reduction threshold.
What the selected report found
This 72-week phase 3 randomized trial found greater average weight reductions with tirzepatide than placebo. The publication also reports tolerability, discontinuations and adverse events.
Results belong to the studied population and trial product. They do not authenticate a separately sold vial or pen.
Keep trial results and product identity separate
Clinical evidence answers a question about a specified intervention. Product documentation answers a different question about a particular item or batch. Reading both is useful; one cannot replace the other. Local product registration and prescribing information require their own current sources.
Source trail
Jastreboff et al. · New England Journal of Medicine · 2022
This is a selected-source reading brief, not a comprehensive literature review, product verification or recommendation to use a compound.